Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca Pledges $287M to Increase Presence in UK | Contract Pharma

What are you searching for?

Sign in
Breaking News

AstraZeneca Pledges $287M to Increase Presence in UK

Plans include a new R&D facility and the expansion of its vaccine manufacturing capabilities.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

AstraZeneca has pledged approximately $827 million to increase its presence in the U.K., including a new R&D facility in Liverpool and the expansion of its vaccine manufacturing capabilities, BioSpace reports.

New Facility in Liverpool

Approximately $573 million of AstraZeneca’s commitment will be used to construct a new facility for the research, development and manufacture of vaccines in Speke, Liverpool. The new campus, which will be designed to be operationally net zero and draw power from renewable sources, is designed to help AstraZeneca produce shots for its global child vaccination program.

Boosting Vaccine Manufacturing Capabilities

As part of its partnership with the U.K. government, AstraZeneca will also partner with the Health Security Agency to boost the country’s resilience against future pandemics. The alliance will leverage innovations at AstraZeneca’s Speke site and the agency’s Vaccine Development Evaluation Center.
 
The remaining $254 million will go toward a separate site at the life sciences cluster in Cambridge. The facility, co-located with AstraZeneca’s R&D Discovery Center, will house 1,000 employees.
 
Wednesday’s announcement also revealed that AstraZeneca will inaugurate a new manufacturing plant in Macclesfield for one of its cancer therapies. In 2021, the pharma company invested around $484 million to construct this facility, which is set to open later this year.
  
This news comes weeks after AstraZeneca invested $300 million in a facility in Rockville, MD to launch its life-saving cell therapy platforms in the U.S. for critical cancer trials and future commercial supply.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics